ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Deals

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Mundipharma and HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. (ShanZeBIO) jointly announced that the two companies have entered into a strategic licensing agreement for REZZAYO/XIUNIS (rezafungin acetate) in Mainland China, Hong Kong,…

November 6, 2026

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

November 6, 2026

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

November 6, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

Company Drug

ADC / XDC

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Empowering Chinese Pharma’s Global Expansion

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu

Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer

About Company